Tryglysin A and B, Novel, Selective, and Potent Antibacterial Agents Against Streptococcus Bacteria
Princeton Docket # 21-3758
Researchers in the Department of Chemistry at Princeton University and the Department of Pharmaceutical Sciences at the University of Illinois at Chicago have identified novel small organic molecules with potent and highly selective antibiotic activity. Tryglysin A and B are novel chemical structures with potent antibiotic activity against a narrow spectrum of bacteria. This narrow spectrum activity indicates the Tryglysins could be working through a novel antibiotic mechanism of action. Due to this narrow spectrum, the Tryglysins could be used as highly targeted therapeutics to treat or prevent disease without disturbing other important, “beneficial” bacteria within the human microbiome, which is a great improvement over virtually all other clinically used antibiotics that are broad-spectrum. The Tryglysins are potent against several streptococcal pathogens, including Streptococcus pneumonia, the leading cause of pneumonia, and Streptococcus mutans, the primary causative agent of tooth decay and gum disease. The Tryglysins are an attractive lead toward the development of therapeutics for the treatment and/or prevention of disease caused by these streptococci.
Stage of Development
Tryglysins have been both isolated and synthetically generated; that is, we have established two methods for the preparation of Tryglysins. We have found that both Tryglysin A and Tryglysin B fully inhibit Streptococcus mutans, Streptococcus ferus, Streptococcus mitis, Streptococcus oralis, and Streptococcus pneumoniae at concentrations of 100 nM. They exhibit a minimal inhibitory concentration (concentration at which the growth of >95% of cells is inhibited) of less than 100 nM.
Quorum Sensing in Streptococcus mutans Regulates Production of Tryglysin, a Novel RaS-RiPP Antimicrobial Compound, Britta E. Rued, Brett C. Covington, Leah B. Bushin, Gabriella Szewczyk, Irina Laczkovich, Mohammad R. Seyedsayamdost, and Michael J. Federle, Published online 2021 Mar 16. doi: 10.1128/mBio.02688-20
Patent protection is pending.
Princeton is currently seeking commercial partners for the further development and commercialization of this opportunity.
Princeton University Office of Technology Licensing
(609) 258-7256 • email@example.com